DARIOHEALTH CORP. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.169 USD | +1.67% |
|
-4.88% | -31.98% |
Financials (USD)
| Sales 2024 * | 38.13M | Sales 2025 * | 49.7M | Capitalization | 33.86M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M | Net income 2025 * | -42M | EV / Sales 2024 * | 0.89 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.68 x |
| P/E ratio 2024 * |
-0.57
x | P/E ratio 2025 * |
-0.81
x | Employees | 285 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.19% |
More Fundamentals
* Assessed data
More news
Latest transcript on DarioHealth Corp.
More recommendations
More press releases
| 1 day | +1.74% | ||
| 1 week | -4.88% | ||
| Current month | -23.53% | ||
| 1 month | -18.18% | ||
| 3 months | -49.13% | ||
| 6 months | -57.14% | ||
| Current year | -31.98% |
1 week
1.05
1.27
1 month
1.051.66
Current year
1.052.60
1 year
0.684.58
3 years
0.6823.80
5 years
0.6831.85
10 years
0.683 258.00
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Raphael
CEO | Chief Executive Officer | 51 | 12-09-30 |
Dov Oppenheim
FOU | Founder | - | 11-08-10 |
Zvi Ben-David
DFI | Director of Finance/CFO | 63 | 15-01-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dennis McGrath
BRD | Director/Board Member | 67 | 13-11-11 |
Adam Stern
BRD | Director/Board Member | 60 | 11-10-26 |
Yoav Shaked
CHM | Chairman | 52 | 18-07-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.169 | +1.67% | 44 594 |
| 24-04-18 | 1.15 | -4.96% | 95,845 |
| 24-04-17 | 1.21 | +3.42% | 59,906 |
| 24-04-16 | 1.17 | +2.63% | 39,154 |
| 24-04-15 | 1.14 | -7.32% | 164,596 |
Delayed Quote Nasdaq, April 19, 2024 at 03:56 pm EDT
More quotes
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.15
USD
Average target price
5.667
USD
Spread / Average Target
+392.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.98% | 33.86M | |
| -2.33% | 183B | |
| -3.65% | 105B | |
| +5.50% | 51.77B | |
| +16.57% | 47.29B | |
| -1.73% | 40.2B | |
| +5.94% | 27.62B | |
| -1.98% | 25.51B | |
| +9.84% | 24.73B | |
| -1.69% | 24.52B |
- Stock Market
- Equities
- DRIO Stock
